AroCell AB (AROC) - Total Liabilities

Latest as of March 2025: Skr14.01 Million SEK ≈ $1.51 Million USD

Based on the latest financial reports, AroCell AB (AROC) has total liabilities worth Skr14.01 Million SEK (≈ $1.51 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AroCell AB net asset momentum to track the company's year-over-year net asset growth rate.

AroCell AB - Total Liabilities Trend (2007–2024)

This chart illustrates how AroCell AB's total liabilities have evolved over time, based on quarterly financial data. See AroCell AB free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

AroCell AB Competitors by Total Liabilities

The table below lists competitors of AroCell AB ranked by their total liabilities.

Company Country Total Liabilities
UDAYSHIVAKUMAR INFRA ORD (BSE)
NSE:USK
India Rs1.64 Billion
Chibougamau Independent Mines Inc
V:CBG
Canada CA$36.03K
Immunovia publ AB
ST:IMMNOV
Sweden Skr19.20 Million
Energisme
PA:ALNRG
France €13.29 Million
Sejoong Co. Ltd
KQ:039310
Korea ₩15.13 Billion
Melbana Energy Ltd
AU:MAY
Australia AU$24.24 Million
High Coast Distillery AB
ST:HIGHCO-B
Sweden Skr146.26 Million
Mynd.ai, Inc.
NYSE MKT:MYND
USA $203.97 Million

Liability Composition Analysis (2007–2024)

This chart breaks down AroCell AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is AroCell AB worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.69 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.13 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.11 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how AroCell AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for AroCell AB (2007–2024)

The table below shows the annual total liabilities of AroCell AB from 2007 to 2024.

Year Total Liabilities Change
2024-12-31 Skr12.93 Million
≈ $1.39 Million
+14.96%
2023-12-31 Skr11.25 Million
≈ $1.21 Million
-15.56%
2022-12-31 Skr13.32 Million
≈ $1.43 Million
+33.71%
2021-12-31 Skr9.96 Million
≈ $1.07 Million
+136.21%
2020-12-31 Skr4.22 Million
≈ $453.82K
-61.55%
2019-12-31 Skr10.97 Million
≈ $1.18 Million
+277.58%
2018-12-31 Skr2.90 Million
≈ $312.62K
+2.44%
2017-12-31 Skr2.84 Million
≈ $305.18K
-4.37%
2016-12-31 Skr2.97 Million
≈ $319.13K
+81.72%
2015-12-31 Skr1.63 Million
≈ $175.61K
-43.38%
2014-12-31 Skr2.88 Million
≈ $310.18K
+26.74%
2013-12-31 Skr2.27 Million
≈ $244.74K
+24.27%
2012-12-31 Skr1.83 Million
≈ $196.94K
-17.52%
2011-12-31 Skr2.22 Million
≈ $238.76K
-8.88%
2010-12-31 Skr2.43 Million
≈ $262.04K
-18.89%
2009-12-31 Skr3.00 Million
≈ $323.06K
+312.36%
2008-12-31 Skr728.00K
≈ $78.34K
+31.88%
2007-12-31 Skr552.00K
≈ $59.40K
--

About AroCell AB

ST:AROC Sweden Diagnostics & Research
Market Cap
$13.39 Million
Skr124.39 Million SEK
Market Cap Rank
#26266 Global
#557 in Sweden
Share Price
Skr0.54
Change (1 day)
+0.00%
52-Week Range
Skr0.54 - Skr0.54
All Time High
Skr15.05
About

AroCell AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cell; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB… Read more